NEW YORK, May 26 (Reuters) - Shares of United Therapeutics (UTHR.O) rose 9.7 percent to $73.01 in premarket trading on Tuesday after the FDA approved its orally administered drug tadalafil for the treatment of pulmonary arterial hypertension.
For details, see [ID:nBNG59984] (Reporting by Ryan Vlastelica, Editing by Walker Simon)
Protesters around the globe called for an end to global warming as climate talks in Copenhagen entered their sixth day. Video
Backed by Americans outraged by multi-billion dollar bailouts, President Obama met with a dozen of Wall Street's top bankers in a bid to crack down on the so-called "fat cats" largely held responsible for the financial crisis. Full Article
The future demands of cybersecurity make that sector one of many the aerospace giant sees as an acquisition target in the coming year. Full Article
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
